-
公开(公告)号:US20250042933A1
公开(公告)日:2025-02-06
申请号:US18774442
申请日:2024-07-16
Inventor: Naoki Watanabe , Youhei Satou , Shin'ichi Takeda , Tetsuya Nagata
IPC: C07H21/04 , C07H21/00 , C12N15/11 , C12N15/113
Abstract: The present invention provides a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency. The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene.
-
公开(公告)号:US20250034098A1
公开(公告)日:2025-01-30
申请号:US18918427
申请日:2024-10-17
Applicant: NIPPON SHINYAKU CO., LTD.
Inventor: Toshio FUJIWARA
IPC: C07D241/20 , C07D241/26
Abstract: A main object of the present invention is to provide a novel crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}acetic acid (hereinafter referred to as “Compound B”). A form-I crystal of Compound B, which shows peaks at diffraction angles (2θ) of 6.4°, 8.1°, 9.5°, 10.9°, 13.2°, 15.7°, 17.0°, 19.5°, 20.3°, 21.0°, and 22.8° in a powder X-ray diffraction spectrum obtained using a Cu-Kα radiation (λ=1.54 Å). A form-II crystal of Compound B, which shows peaks at diffraction angles (2θ) of 9.6°, 11.4°, 11.7°, 16.3°, 17.5°, 18.5°, 18.7°, 19.9°, 20.1°, 21.0°, and 24.6° in a powder X-ray diffraction spectrum obtained using a Cu-Kα radiation (λ=1.54 Å).
-
公开(公告)号:US20240199309A1
公开(公告)日:2024-06-20
申请号:US18591369
申请日:2024-02-29
Applicant: NIPPON SHINYAKU CO., LTD.
Inventor: Masaki HAYAKAWA
IPC: B65D83/04
CPC classification number: B65D83/0409
Abstract: A measuring container comprises a storage container and a storage section selector. The storage container includes storage sections each capable of storing a predetermined number of tablets. The storage section selector is attached to the storage container and has a second path that allows the tablets to pass through from one end to an other end. The one end of the second path is connected to an outside, and the other end is selectively connected to one of the storage sections.
-
公开(公告)号:US20230045557A1
公开(公告)日:2023-02-09
申请号:US17785565
申请日:2020-12-18
Inventor: Naoki WATANABE , Yuichiro TONE , Shin'ichi TAKEDA , Yoshitsugu AOKI
IPC: C12N15/113
Abstract: The present specification provides an antisense oligomer capable of causing simultaneous skipping of a plurality of exons in pre-mRNA of interest, and a pharmaceutical composition comprising the oligomer. The present specification also provides an antisense oligomer or a pharmaceutically acceptable salt thereof, or hydrate thereof which causes simultaneous skipping of two or more numerically consecutive exons from pre-mRNA of interest, the antisense oligomer comprising a base sequence complementary to a base sequence of a region including the vicinity of a donor of any intron in the pre-mRNA of interest, or a region including the vicinity of an acceptor of any intron in the pre-mRNA of interest, or a partial base sequence thereof.
-
公开(公告)号:US20220227567A1
公开(公告)日:2022-07-21
申请号:US17605611
申请日:2020-04-08
Applicant: NIPPON SHINYAKU CO., LTD.
Inventor: Masaki HAYAKAWA
IPC: B65D83/04
Abstract: A measuring container comprises a storage container and a storage section selector. The storage container includes storage sections each capable of storing a predetermined number of tablets. The storage section selector is attached to the storage container and has a second path that allows the tablets to pass through from one end to an other end. The one end of the second path is connected to an outside, and the other end is selectively connected to one of the storage sections.
-
公开(公告)号:US11377453B2
公开(公告)日:2022-07-05
申请号:US17035947
申请日:2020-09-29
Applicant: NIPPON SHINYAKU CO., LTD.
Inventor: Fumi Higuchi
IPC: C07D513/00 , A61P29/00 , A61P35/00 , A61P37/06 , C07C309/30 , A61K31/506 , A61P11/00 , A61P25/00 , A61P37/00 , C07D513/04
Abstract: An object of the present invention is to provide a compound with an excellent JAK1 inhibitory activity.
The compound of the invention has JAK1 inhibitory activity, and thus, immunosuppressive effect, anti-inflammatory effect, anti-proliferative effect and so on, and is useful in the treatment of the diseases, for example, rheumatoid arthritis, inflammatory bowel disease, psoriasis, vasculitis, bronchial asthma, chronic obstructive pulmonary disease, eosinophilic sinusitis and nasal polyp.-
公开(公告)号:US20220162604A1
公开(公告)日:2022-05-26
申请号:US17364618
申请日:2021-06-30
Inventor: Tatsushi WAKAYAMA , Haruna SEO , Youhei SATOU , Shin'ichi TAKEDA , Tetsuya NAGATA
IPC: C12N15/113 , A61K31/713 , C12N15/11
Abstract: Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene. The present invention provides an antisense oligomer which enables exon 51 in the human dystrophin gene to be skipped.
-
公开(公告)号:US20210284680A1
公开(公告)日:2021-09-16
申请号:US17333677
申请日:2021-05-28
Inventor: Naoki WATANABE , Youhei SATOU , Shin'ichi TAKEDA , Tetsuya NAGATA
IPC: C07H21/04 , C12N15/113 , C12N15/11 , C07H21/00
Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.
-
公开(公告)号:US11053497B2
公开(公告)日:2021-07-06
申请号:US16437130
申请日:2019-06-11
Inventor: Tatsushi Wakayama , Haruna Seo , Youhei Satou , Shin'ichi Takeda , Tetsuya Nagata
IPC: C12N15/113 , A61K31/713 , C12N15/11
Abstract: Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene. The present invention provides an antisense oligomer which enables exon 51 in the human dystrophin gene to be skipped.
-
公开(公告)号:US20200223804A1
公开(公告)日:2020-07-16
申请号:US16650390
申请日:2018-09-27
Applicant: NIPPON SHINYAKU CO., LTD.
Inventor: Toshio FUJIWARA
IPC: C07D241/20
Abstract: A main object of the present invention is to provide a novel crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}acetic acid (hereinafter referred to as “Compound B”).A form-I crystal of Compound B, which shows peaks at diffraction angles (2θ) of 6.4°, 8.1°, 9.5°, 10.9°, 13.2°, 15.7°, 17.0°, 19.5°, 20.3°, 21.0°, and 22.8° in a powder X-ray diffraction spectrum obtained using a Cu-Kα radiation (λ=1.54 Å).A form-III crystal of Compound B, which shows peaks at diffraction angles (2θ) of 9.6°, 11.4°, 11.7°, 16.3°, 17.5°, 18.5°, 18.7°, 19.9°, 20.1°, 21.0°, and 24.6° in a powder X-ray diffraction spectrum obtained using a Cu-Kα radiation (λ=1.54 Å).
-
-
-
-
-
-
-
-
-